Diffusion Pharmaceuticals Inc. (DFFN) News
Filter DFFN News Items
DFFN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DFFN News From Around the Web
Below are the latest news stories about DIFFUSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DFFN as an investment opportunity.
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative DiseasesCombined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 202 |
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special OpportunitiesLifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to d |
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-DealingClosing Dates of LifeSci-led Mergers Closing Dates of LifeSci-led Mergers Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review processLifeSci invited to participate in review process on same terms as all other bidders following submission of client’s unsolicited offer, but LifeSci instead chose to launch a proxy contest against our high |
DFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23…By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating Strategic Opportunities On November 14, 2022, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) provided an update for its previously announced evaluation of strategic opportunities, which may include a sale, merger, divestiture, recapitalization, or other strategic transaction. Since announcing its |
LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion PharmaceuticalsSets the Record Straight on Diffusion’s Misleading Narrative and Raises Concerns about a Troubling Pattern of Entrenchment and Lack of Accountability on the Board Has Nominated a Slate of Highly Qualified Directors NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- LifeSci Special Opportunities Master Fund Ltd. (“LifeSci Special Opportunities” or “we”), the holder of 96,976 shares of common stock of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”) (NASDAQ: DFFN), or approximately 4.8% of t |
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateAnnounced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financ |
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review ProcessDiffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client’s Offer Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process Date of Diffusion’s 2022 Annual Meeting of Stockholders Set |
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSCCHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that its Board of Directors (the “Board”) has authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value including transactiona |
DFFN: Phase 2 GBM Trial to Initiate 2H22…By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Phase 2 GBM Trial to Initiate in 2H22 In July 2022, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the company had aligned with the U.S. Food and Drug Administration (FDA) on the design of an open label, dose escalation, Phase 2 safety and efficacy study (Study 200-208) of its lead development |